Experimental Drug Reverses Fatty Liver Disease by Targeting Gut Bacteria

A New Strategy for MASH Targets the Gut-Liver Connection

Researchers at Michigan Medicine have demonstrated that an experimental compound called DT-109 successfully reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal studies by addressing a counterintuitive target: harmful bacteria in the gut. The findings, published in The Journal of Clinical Investigation, reveal that the disease's progression is deeply connected to intestinal health and microbial imbalances, rather than being purely a liver-specific disorder. This discovery opens a novel therapeutic avenue for a condition affecting roughly 7% of the global population, for which treatment options remain limited despite recent improvements.

MASH represents a severe form of fatty liver disease in which excessive fat accumulates in the liver, triggering inflammation and cellular damage. Without intervention, the condition can progress to cirrhosis—extensive liver scarring—and ultimately lead to liver cancer and liver failure. The disease has proven difficult to manage clinically, making the identification of new treatment approaches a significant priority.

How Gut Bacteria Damage the Liver

The research team uncovered the specific mechanism linking gut dysfunction to liver damage. Scientists confirmed that excessive growth of Clostridium perfringens, a bacterium that generates ammonia in the intestines, plays a critical role in MASH development. When ammonia levels rise, they damage the intestinal barrier—the protective lining that normally prevents harmful substances from entering the bloodstream. As this barrier weakens, microbial toxins and other products escape the digestive tract and travel via the bloodstream to the liver.

Once these harmful substances reach the liver, they trigger inflammation and activate immune responses that exacerbate liver injury. Specifically, the research identified excessive activation of CD8+ T cells, immune cells that normally help destroy infected or abnormal cells. When overactivated, these cells contribute to the inflammatory cascade underlying MASH. This chain reaction demonstrates why a disease centered in the liver can be dramatically influenced by processes occurring in the distant digestive system—a relationship termed the gut-liver axis.

DT-109 Breaks the Damaging Cycle

DT-109, classified as a glycine-based tripeptide (a small molecule composed of three amino acids), disrupts this harmful cycle by improving the intestinal environment and reinforcing the gut's protective barrier. In experiments using both mice and nonhuman primates, the compound reduced Clostridium perfringens levels and lowered ammonia production in the intestines. These changes strengthened the intestinal lining, limiting microbial substances' movement into the body and reducing their potential to damage the liver.

Results proved particularly encouraging in nonhuman primates, whose liver biology and gut microbial communities more closely resemble human physiology than those of mice. In these animals, DT-109 reduced liver inflammation and decreased MASH severity. The compound's effectiveness despite acting primarily within the gastrointestinal system demonstrates how targeting the root cause of inflammation outside the liver can produce protective benefits within the organ itself. By restoring gut barrier integrity and limiting the systemic circulation of ammonia and pro-inflammatory microbial products, DT-109 addresses underlying pathological processes rather than merely treating already-established damage.

Broader Therapeutic Potential and Next Steps

Beyond MASH, researchers believe DT-109's capacity to protect the intestinal barrier could extend to other inflammatory and metabolic conditions. Previous research has demonstrated the compound's ability to reduce atherosclerotic plaque formation and prevent vascular calcification in nonhuman primates—findings suggesting potential applications in cardiovascular disease treatment. This possibility carries particular significance given that metabolic disorders typically affect multiple organ systems simultaneously, making a single therapeutic approach that addresses both liver and heart health especially valuable.

Scientists are also exploring whether DT-109 might help patients with inflammatory bowel disease, including Crohn's disease and ulcerative colitis, since intestinal barrier dysfunction underlies several gastrointestinal disorders. However, additional research remains necessary to establish efficacy against these conditions.

Despite these encouraging results, DT-109 remains experimental. Researchers have demonstrated its efficacy in animal models but have not yet established whether it can safely and effectively produce similar benefits in humans. The next research phase involves further compound evaluation, with the ultimate goal of advancing toward human clinical trials. Those studies will be essential for determining safety, appropriate dosing, and clinical effectiveness. The research represents a fundamental shift in how scientists approach fatty liver disease—addressing the disease not exclusively through direct liver intervention but by restoring digestive system health and preventing systemic inflammation originating in the gut.